Entheos Labs
Discovery1 active candidate
2 shared indicationsDiscovery peersimilar active pipeline sizeboth have forecast coverage
Back to StakeholdersProgramme tracker View landscape
Lead program: Discovery
Categories
1 domain / 2 areas / 1 specialization
Elkedonia
Data updated
1 Drug Candidate
Elkedonia is a French neuroplastogen biotech developing novel small molecules targeting the Elk-1 transcription factor, a key regulator of neuroplasticity within neuronal cells. Backed by €11 million in funding, the company is advancing clinical research into next-generation antidepressants that promote neuroplasticity without the adverse effects of traditional treatments, with CEO Delphine Charvin leading the programme.
Pipeline Intelligence
Developer Momentum
- Active candidates
- 1
- Active programmes
- 1
- Lead stage
- Discovery
- Forecast coverage
- 1 of 1
All tracked candidates active
All tracked programmes active
Current furthest stage
1 active programme with forecast fields
Latest sourced update
Elkedonia Raises 11.25M Seed Round to Advance Neuroplastogen Therapy
Jun 19, 2026 - industry-media - Pharmaceutical Technology - Elk1 Small Molecule Neuroplastogens
Next known catalyst
candidate-selection
Timing not specified - Elk1 Small Molecule Neuroplastogens / Elk1 Neuroplastogen Discovery Programme (Depression) - Confidence: 25%
3 sources0 pipeline-linked trials0 pipeline-linked papers
Development Programmes
1Elk1 Small Molecule Neuroplastogens
Discovery
Treatment-resistant depression / neuropsychiatric disorders
Programme Tracker
Major Depressive Disorder (MDD)
Primary: EU (EMA)
DiscoveryActive
Forecast
candidate-selection
Discovery/lead-optimization stage; Elkedonia launched with an 11.25M seed round in June 2025 and recent coverage continues to describe first-in-class Elk1 inhibitors for treatment-resistant depression.
Milestones
Company milestone
CompletedActual: Jan 1, 2024
Elkedonia founded by Argobio venture studio (Paris), spun out from translational research by Dr Jocelyne Caboche at Sorbonne University
Why it matters: Elkedonia targets the Elk-1 transcription factor — an intracellular regulator of synaptic plasticity genes previously considered "undruggable." This is a wholly distinct neuroplasticity mechanism from classical psychedelics (5-HT2A) and ketamine (NMDA), potentially producing antidepressant effects without psychoactive properties.
Funding milestone
CompletedActual: Jun 11, 2025
Closed oversubscribed €11.25M seed round co-led by Kurma Partners, WE Life Sciences, and Bpifrance; participation from Angelini Ventures, Argobio, Carma Fund, Capital Grand Est, Sambrinvest
Why it matters: Well-capitalized seed round from top European life science VCs validates the Elk1 target biology. Angelini Ventures (pharma corporate VC) participation signals commercial interest. Funds will advance lead optimization toward IND-enabling preclinical studies.
Watch next: Lead candidate nomination and IND-enabling studies
Company milestone
CompletedActual: Jun 11, 2025
Delphine Charvin appointed CEO (transitioned from Argobio Operating Partner)
Why it matters: Experienced drug development leadership in place as company transitions from academic spinout to IND-track biotech.
Recorded Events
Jun 11, 2025: Funding milestone
Jun 11, 2025: Company milestone
Jan 1, 2024: Company milestone
Evidence Links
Argobio Announces Launch of Elkedonia with 11M Seed Round
Press release - Argobio Studio - Jun 11, 2025 - Verified
Launch announcement says proceeds support first-in-class fast-acting neuroplastogens for TRD and other neuropsychiatric disorders.
Elkedonia Raises 11.25M Seed Round to Advance Neuroplastogen Therapy
industry-media - Pharmaceutical Technology - Jun 19, 2026 - Verified
Recent coverage describes Elkedonia developing first-in-class Elk1 inhibitors for treatment-resistant depression.
Similar Developers
Reference points selected from shared pipeline stage, indications, compounds, regulatory pathways, and evidence footprint.
CB Therapeutics
Discovery2 active candidates
2 shared indicationsDiscovery peersimilar active pipeline sizeboth have forecast coverage
Biomia
Discovery1 active candidate
same indication: Major Depressive Disorder (MDD)Discovery peersame regulator: EU EMAsimilar active pipeline size
Lophora
Phase I2 active candidates
2 shared indicationssame regulator: EU EMAsimilar active pipeline sizeboth have forecast coverage
Quick Facts
- Type
- Private Biotech
- Lead Stage
- Discovery
- Website
- Visit